Everolimus in pulmonary transplantation: Pharmacokinetics and exposure-response relationships

John M. Kovarik, Gregory I. Snell, Vincent Valentine, Robert Aris, Charles K N Chan, Heinz Schmidli, Ulrich Pirron

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background: In this study we evaluated exposure, safety and efficacy data from an international trial of everolimus. We sought to identify a tolerated and efficacious range for blood levels of this agent in maintenance lung transplant recipients. Methods: In a randomized, double-blind, multicenter trial, 213 maintenance lung transplant recipients received either everolimus 1.5 mg twice daily (n = 101) or azathioprine 1 to 3 mg/kg/day (n = 112) with cyclosporine and corticosteroids. At 15 visits over the first 2 years of the trial, we obtained 826 everolimus trough (C0) blood samples. We used median-effect analysis to assess relationships between everolimus C0 vs efficacy and safety responses. Results: Everolimus administration began at 1.5 mg twice daily and was progressively lowered over the first 2 months to an average of 1.2 ± 0.4 mg twice daily, which was maintained thereafter. This dose yielded median C0 levels of 6.6 ng/ml (10th to 90th percentiles: 2.8 to 11.8 ng/ml). Over this range of everolimus C0, freedom from a decline in pulmonary function with bronchiolitis obliterans syndrome and freedom from biopsy-proven acute rejection were both <88%. The incidence of increased cholesterol (>6.5 mmol/liter), increased triglycerides (>2.9 mmol/liter) and transiently decreased platelet count (<100 × 109/liter) rose significantly with increasing C0. Infections and drug-related adverse events were not significantly related to exposure. Conclusions: A tolerated and efficacious concentration range for everolimus in maintenance lung transplantation appears to be 3 to 12 ng/ml when used in conjunction with cyclosporine and corticosteroids. This range should be prospectively assessed with possible refinement as more clinical experience is gained.

Original languageEnglish (US)
Pages (from-to)440-446
Number of pages7
JournalJournal of Heart and Lung Transplantation
Volume25
Issue number4
DOIs
StatePublished - Apr 2006
Externally publishedYes

Fingerprint

Lung Transplantation
Pharmacokinetics
Maintenance
Lung
Cyclosporine
Adrenal Cortex Hormones
Bronchiolitis Obliterans
Safety
Azathioprine
Everolimus
Drug-Related Side Effects and Adverse Reactions
Platelet Count
Multicenter Studies
Triglycerides
Biopsy
Infection

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Transplantation

Cite this

Kovarik, J. M., Snell, G. I., Valentine, V., Aris, R., Chan, C. K. N., Schmidli, H., & Pirron, U. (2006). Everolimus in pulmonary transplantation: Pharmacokinetics and exposure-response relationships. Journal of Heart and Lung Transplantation, 25(4), 440-446. https://doi.org/10.1016/j.healun.2005.12.001

Everolimus in pulmonary transplantation : Pharmacokinetics and exposure-response relationships. / Kovarik, John M.; Snell, Gregory I.; Valentine, Vincent; Aris, Robert; Chan, Charles K N; Schmidli, Heinz; Pirron, Ulrich.

In: Journal of Heart and Lung Transplantation, Vol. 25, No. 4, 04.2006, p. 440-446.

Research output: Contribution to journalArticle

Kovarik, JM, Snell, GI, Valentine, V, Aris, R, Chan, CKN, Schmidli, H & Pirron, U 2006, 'Everolimus in pulmonary transplantation: Pharmacokinetics and exposure-response relationships', Journal of Heart and Lung Transplantation, vol. 25, no. 4, pp. 440-446. https://doi.org/10.1016/j.healun.2005.12.001
Kovarik, John M. ; Snell, Gregory I. ; Valentine, Vincent ; Aris, Robert ; Chan, Charles K N ; Schmidli, Heinz ; Pirron, Ulrich. / Everolimus in pulmonary transplantation : Pharmacokinetics and exposure-response relationships. In: Journal of Heart and Lung Transplantation. 2006 ; Vol. 25, No. 4. pp. 440-446.
@article{023e17ed543346f9bb6358c2ba2eff93,
title = "Everolimus in pulmonary transplantation: Pharmacokinetics and exposure-response relationships",
abstract = "Background: In this study we evaluated exposure, safety and efficacy data from an international trial of everolimus. We sought to identify a tolerated and efficacious range for blood levels of this agent in maintenance lung transplant recipients. Methods: In a randomized, double-blind, multicenter trial, 213 maintenance lung transplant recipients received either everolimus 1.5 mg twice daily (n = 101) or azathioprine 1 to 3 mg/kg/day (n = 112) with cyclosporine and corticosteroids. At 15 visits over the first 2 years of the trial, we obtained 826 everolimus trough (C0) blood samples. We used median-effect analysis to assess relationships between everolimus C0 vs efficacy and safety responses. Results: Everolimus administration began at 1.5 mg twice daily and was progressively lowered over the first 2 months to an average of 1.2 ± 0.4 mg twice daily, which was maintained thereafter. This dose yielded median C0 levels of 6.6 ng/ml (10th to 90th percentiles: 2.8 to 11.8 ng/ml). Over this range of everolimus C0, freedom from a decline in pulmonary function with bronchiolitis obliterans syndrome and freedom from biopsy-proven acute rejection were both <88{\%}. The incidence of increased cholesterol (>6.5 mmol/liter), increased triglycerides (>2.9 mmol/liter) and transiently decreased platelet count (<100 × 109/liter) rose significantly with increasing C0. Infections and drug-related adverse events were not significantly related to exposure. Conclusions: A tolerated and efficacious concentration range for everolimus in maintenance lung transplantation appears to be 3 to 12 ng/ml when used in conjunction with cyclosporine and corticosteroids. This range should be prospectively assessed with possible refinement as more clinical experience is gained.",
author = "Kovarik, {John M.} and Snell, {Gregory I.} and Vincent Valentine and Robert Aris and Chan, {Charles K N} and Heinz Schmidli and Ulrich Pirron",
year = "2006",
month = "4",
doi = "10.1016/j.healun.2005.12.001",
language = "English (US)",
volume = "25",
pages = "440--446",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Everolimus in pulmonary transplantation

T2 - Pharmacokinetics and exposure-response relationships

AU - Kovarik, John M.

AU - Snell, Gregory I.

AU - Valentine, Vincent

AU - Aris, Robert

AU - Chan, Charles K N

AU - Schmidli, Heinz

AU - Pirron, Ulrich

PY - 2006/4

Y1 - 2006/4

N2 - Background: In this study we evaluated exposure, safety and efficacy data from an international trial of everolimus. We sought to identify a tolerated and efficacious range for blood levels of this agent in maintenance lung transplant recipients. Methods: In a randomized, double-blind, multicenter trial, 213 maintenance lung transplant recipients received either everolimus 1.5 mg twice daily (n = 101) or azathioprine 1 to 3 mg/kg/day (n = 112) with cyclosporine and corticosteroids. At 15 visits over the first 2 years of the trial, we obtained 826 everolimus trough (C0) blood samples. We used median-effect analysis to assess relationships between everolimus C0 vs efficacy and safety responses. Results: Everolimus administration began at 1.5 mg twice daily and was progressively lowered over the first 2 months to an average of 1.2 ± 0.4 mg twice daily, which was maintained thereafter. This dose yielded median C0 levels of 6.6 ng/ml (10th to 90th percentiles: 2.8 to 11.8 ng/ml). Over this range of everolimus C0, freedom from a decline in pulmonary function with bronchiolitis obliterans syndrome and freedom from biopsy-proven acute rejection were both <88%. The incidence of increased cholesterol (>6.5 mmol/liter), increased triglycerides (>2.9 mmol/liter) and transiently decreased platelet count (<100 × 109/liter) rose significantly with increasing C0. Infections and drug-related adverse events were not significantly related to exposure. Conclusions: A tolerated and efficacious concentration range for everolimus in maintenance lung transplantation appears to be 3 to 12 ng/ml when used in conjunction with cyclosporine and corticosteroids. This range should be prospectively assessed with possible refinement as more clinical experience is gained.

AB - Background: In this study we evaluated exposure, safety and efficacy data from an international trial of everolimus. We sought to identify a tolerated and efficacious range for blood levels of this agent in maintenance lung transplant recipients. Methods: In a randomized, double-blind, multicenter trial, 213 maintenance lung transplant recipients received either everolimus 1.5 mg twice daily (n = 101) or azathioprine 1 to 3 mg/kg/day (n = 112) with cyclosporine and corticosteroids. At 15 visits over the first 2 years of the trial, we obtained 826 everolimus trough (C0) blood samples. We used median-effect analysis to assess relationships between everolimus C0 vs efficacy and safety responses. Results: Everolimus administration began at 1.5 mg twice daily and was progressively lowered over the first 2 months to an average of 1.2 ± 0.4 mg twice daily, which was maintained thereafter. This dose yielded median C0 levels of 6.6 ng/ml (10th to 90th percentiles: 2.8 to 11.8 ng/ml). Over this range of everolimus C0, freedom from a decline in pulmonary function with bronchiolitis obliterans syndrome and freedom from biopsy-proven acute rejection were both <88%. The incidence of increased cholesterol (>6.5 mmol/liter), increased triglycerides (>2.9 mmol/liter) and transiently decreased platelet count (<100 × 109/liter) rose significantly with increasing C0. Infections and drug-related adverse events were not significantly related to exposure. Conclusions: A tolerated and efficacious concentration range for everolimus in maintenance lung transplantation appears to be 3 to 12 ng/ml when used in conjunction with cyclosporine and corticosteroids. This range should be prospectively assessed with possible refinement as more clinical experience is gained.

UR - http://www.scopus.com/inward/record.url?scp=33645070240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645070240&partnerID=8YFLogxK

U2 - 10.1016/j.healun.2005.12.001

DO - 10.1016/j.healun.2005.12.001

M3 - Article

C2 - 16563975

AN - SCOPUS:33645070240

VL - 25

SP - 440

EP - 446

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 4

ER -